Investigation of Paclitaxel Resistant R306C Mutation in β-Tubulin—A Computational Approach.
Paclitaxel is the most effective chemotherapeutic agent used for the treatment of a broad spectrum of solid tumors. However, observed paclitaxel resistance in clinical trials presents one of the major obstacles for cancer chemotherapy. Most importantly, resistance due to β-tubulin mutations (R306C) has been intensely debated in recent years. Despite all efforts, mechanism of resistance is still not well understood. In this study, computational techniques were employed to uncover the effect of R306C mutation in the β-tubulin structure and its function. The tools such as I-Mutant, CUPSAT and Fold-X were employed to address the consequence of R306C mutation in the structural stability of β-tubulin. Further, molecular docking and molecular dynamics study was employed to understand the functional impact of β-tubulin mutation. Our results suggest that the R306C mutation causes a significant reduction in the binding affinity between β-tubulin and paclitaxel. Further, docked complex analysis indicates that destruction of conservative hydrogen bond maintained by the residues Arg282 and Gly360 should be responsible for the large conformation changes of the binding pocket in R306C mutant. Finally, molecular dynamics simulations study confirms the stable binding of paclitaxel with native type β-tubulin structure rather than mutant (R306C) type. We certainly believe that this study will provide useful guidance for the development of novel inhibitors that are less susceptible to drug resistance.
Industrial Biotechnology Division, School of Bio Sciences and Technology, VIT University, Vellore, 632014, Tamil Nadu, India.
Kanika
K
Verma
Industrial Biotechnology Division, School of Bio Sciences and Technology, VIT University, Vellore, 632014, Tamil Nadu, India.
K
K
Ramanathan
D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D001120:Arginine / Q000378:metabolism; D001665:Binding Sites; D019295:Computational Biology / Q000379:methods*; D003545:Cysteine / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D006801:Humans; D006860:Hydrogen Bonding; D062105:Molecular Docking Simulation; D056004:Molecular Dynamics Simulation; D009154:Mutation; D017239:Paclitaxel / Q000494:pharmacology*; D011485:Protein Binding; D055550:Protein Stability; D014404:Tubulin / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism
D000972:Antineoplastic Agents, Phytogenic; D014404:Tubulin; D001120:Arginine; D003545:Cysteine; D017239:Paclitaxel
MOLECULAR DOCKING; MOLECULAR DYNAMICS; PACLITAXEL; R306C MUTATION